These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9214204)

  • 1. [Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels].
    Ferrero Doria R; Pérez Flores D; Terrer Artes C; Guzmán Martínez-Valls PL; Morga Egea JP; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Fontana Compiano LO
    Actas Urol Esp; 1997 Feb; 21(2):100-4. PubMed ID: 9214204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
    Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
    J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].
    Grigor'ev ME; Mazo EB; Chekhonin VP
    Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retropubic adenomectomy in patients with a high level of prostate-specific antigen after prostatic biopsy].
    Veliev EI; Kotov SV; Golubtsova EN; Sokolov AE; Bogdanov AB; Avakian AIu
    Urologiia; 2012; (1):59-63. PubMed ID: 22646005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic prostatitis lowers serum prostate specific antigen.
    Bozeman CB; Carver BS; Eastham JA; Venable DD
    J Urol; 2002 Apr; 167(4):1723-6. PubMed ID: 11912396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
    Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
    Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen levels in acute and chronic bacterial prostatitis.
    Yamamoto M; Hibi H; Miyake K
    Hinyokika Kiyo; 1993 May; 39(5):445-9. PubMed ID: 7686714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical analysis of benign prostatic hyperplasia with chronic prostatitis].
    Wu XJ; Yang LY; Zhang XZ
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):527-9. PubMed ID: 18649752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.